NeoStem, Inc. (NYSE MKT:NBS), an
emerging leader in the fast growing cell therapy market, announced today that
data from its collaborative studies with the University of Michigan School of
Dentistry further expands the therapeutic potential of its proprietary
regenerative cell therapy product, "VSELS^TM" (very small embryonic-like stem
cells), by demonstrating bone regeneration capabilities in a study published
online ahead of print^1 in the journal Stem Cells and Development (DOI:
10.1089/scd.2012.0327). The paper highlights that human VSEL stem cells form
human bone when implanted in the bone tissue of SCID mice.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in